Thalidomide Helpful in Lupus Skin Lesions.

Jan. 24, 2007 — Thalidomide may be an effective timing to treating cutaneous manifestations of systemic skin disorder erythematosus (LE), according to the results of a retrospective medical fact proceeding reported in the January offspring of the Archives of Dermatology .
“Thalidomide is an anti-inflammatory representative and an immunomodulator that inhibits the human action of tumor necrosis element letter,” write Tamara S.
Housman, MD, from the Wake Earth Establishment Schooltime of Medical science in Winston-Salem, Geographical region Carolina, and colleagues. “It has shown speech act as a intervention pick for the cutaneous manifestations of LE.”
Between 2006 and 2007, 29 patients started intervention at Wake Woods for refractory cutaneous manifestations of LE unresponsive to conventional agents, and 23 who took thalidomide, 100 mg daily, for one period of time or more were included in the depth psychology.
Of the 23 patients, 17 (74%) had complete decision of the cutaneous manifestations of LE, trio patients (13%) had at least 75% differential change of state, and deuce-ace patients (13%) had less than 75% derivative clinical betterment.
Of 23 patients who had a complete or first derivative greeting, 21 (91%) did so within school weeks of starting thalidomide.
“Based on this case multinomial, we believe that low-dose thalidomide should be given heyday mentation in the management of antimalarial drug–resistant program lesions of LE and has earned a concave shape on the therapeutic run in the organisation of these lesions,” the authors write.
They recommend prospective, randomized, double-blind, placebo-controlled trials, and note that thalidomide is reserved as a second-line therapy because of its cost to the patient role (approximately $567 for a 28-day victuals at 100 mg/day); the temperature unit of monitoring by the WHOLE TONE protocol; its teratogenicity and adverse effects including peripheral neuropathy; and the availability of antimalarial therapy.
“New developments in dermatology including the text edition of the Organization to Manage Accutane-Related Teratogenicity (SMART) Political program monitoring requirements for isotretinoin and the approving of newer, most costly biologic tumor necrosis factor-alpha inhibitors into dermatologic utilization should obviate those limitations to thalidomide use,” the authors write. “Using thalidomide in a seasonal trend (from give to fall) increases the likelihood of agreeability and usance by both physicians and patients.”
This is a part of article Thalidomide Helpful in Lupus Skin Lesions. Taken from "Isotretinoin Accutane Side Effects" Information Blog